trending Market Intelligence /marketintelligence/en/news-insights/trending/v2-kgRrJ8HO3k1ijZ_MFgA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

LBT Innovations laboratory instrument gets US FDA clearance

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


LBT Innovations laboratory instrument gets US FDA clearance

Australia's LBT Innovations Ltd. said its APAS Independence instrument received the U.S. Food and Drug Administration's 510(k) clearance.

The APAS Independence instrument with associated urine analysis module allows the automatic reading of culture plates, streamlining the plate triaging stage in the microbiology workflow.

The commercial instrument, classified as a class II medical device, was developed by Clever Culture Systems, LBT Innovations' 50%-owned joint venture unit.

Adelaide, South Australia-based LBT Innovations is engaged in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland and the U.S.